Hansoh Pharmaceutical Group Company Limited (03692.HK) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.8x

Market Cap

HKD 217.24B

MomentumView details →

1D Return

+0.78%

YTD Return

+0.44%

RSI (14)

60.8

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

13.8x

Market Cap

HKD 217.24B

RSI (14)

60.8

MomentumView details →

1D Return

+0.78%

YTD Return

+0.44%

ProfitabilityView details →

Gross Margin

90.64%

Net Margin

39.35%

EBITDA Margin

38.18%

ROE (TTM)

30.19%

ROA (TTM)

24.47%

Asset Turnover

0.67x

GrowthView details →

Revenue YoY

+34.40%

EPS YoY

+55.28%

FCF YoY

+40.67%

Revenue CAGR 3Y

+17.00%

EPS CAGR 3Y

+28.33%

EBITDA YoY

+50.05%

EarningsView details →

EPS (Actual)

HKD 0.81

EPS Surprise

43.01%

Beats (12Q)

1/12

Next Q EPS Est

—

Avg Surprise (4Q)

43.01%

Rev Surprise

0.59%

Capital & dividendView details →

Debt/Equity

0.11x

Current Ratio

4.88x

Quick Ratio

4.80x

Div Yield

1.19%

Div Rate

HKD 0.43

Div Growth 1Y

−45.49%

Financials snapshotView financials →

Revenue (TTM)

28.97B

Net Income (TTM)

11.40B

Op. CF (TTM)

9.43B

Next earningsMar 30, 2027 →

Latest newsMore news →

Hansoh Pharmaceutical announced that its self-developed innovative drug HS-20093 for injection has had its marketing authorization application accepted by China's National Medical Products Administration (NMPA) for treating adult patients with small cell lung cancer (SCLC) who have failed prior platinum-based treatment.3d ago

Hansoh Pharmaceutical's stock price rose over 13% on August 27, 2026, reaching a high of HK$36.62, after Morgan Stanley raised its target price to HK$48.9d ago

Similar companies

Boditech Med Inc.206640.KQ Samjin Pharmaceuticals Co., Ltd.005500.KS Yungjin Pharm. Co., Ltd.003520.KS Hyundai Pharmaceutical Co., Ltd.004310.KS Whan In Pharm Co.,Ltd.016580.KS Suheung Co., Ltd.008490.KS Find similar companies →

Latest newsMore news →

Hansoh Pharmaceutical announced that its self-developed innovative drug HS-20093 for injection has had its marketing authorization application accepted by China's National Medical Products Administration (NMPA) for treating adult patients with small cell lung cancer (SCLC) who have failed prior platinum-based treatment.3d ago Hansoh Pharmaceutical's stock price rose over 13% on August 27, 2026, reaching a high of HK$36.62, after Morgan Stanley raised its target price to HK$48.9d ago Hansoh Pharmaceutical declared an interim dividend of 28.5 HK cents per share for H1 2026, up about 23% from 23.16 HK cents in the prior-year period.10d ago